These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 20716021)

  • 21. The safety and efficacy of dose-sparing intradermal administration of influenza vaccine in human immunodeficiency virus-positive patients.
    Khanlou H; Sanchez S; Babaie M; Chien C; Hamwi G; Ricaurte JC; Stein T; Bhatti L; Denouden P; Farthing C
    Arch Intern Med; 2006 Jul; 166(13):1417. PubMed ID: 16832008
    [No Abstract]   [Full Text] [Related]  

  • 22. Comparison between a conventional subunit vaccine and the MF59-adjuvanted subunit influenza vaccine in the elderly: an evaluation of the safety, tolerability and immunogenicity.
    Sindoni D; La Fauci V; Squeri R; Cannavò G; Bacilieri S; Panatto D; Gasparini R; Amicizia D
    J Prev Med Hyg; 2009 Jun; 50(2):121-6. PubMed ID: 20099444
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibody responses after dose-sparing intradermal influenza vaccination.
    Auewarakul P; Kositanont U; Sornsathapornkul P; Tothong P; Kanyok R; Thongcharoen P
    Vaccine; 2007 Jan; 25(4):659-63. PubMed ID: 17011678
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intradermal influenza vaccine and new devices: a promising chance for vaccine improvement.
    Ansaldi F; Durando P; Icardi G
    Expert Opin Biol Ther; 2011 Mar; 11(3):415-27. PubMed ID: 21299438
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum antibody responses after intradermal vaccination against influenza.
    Belshe RB; Newman FK; Cannon J; Duane C; Treanor J; Van Hoecke C; Howe BJ; Dubin G
    N Engl J Med; 2004 Nov; 351(22):2286-94. PubMed ID: 15525713
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.
    Leroux-Roels I; Roman F; Forgus S; Maes C; De Boever F; Dramé M; Gillard P; van der Most R; Van Mechelen M; Hanon E; Leroux-Roels G
    Vaccine; 2010 Jan; 28(3):849-57. PubMed ID: 19835828
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunogenicity and Safety of H5N1 A/Vietnam/1194/2004 (Clade 1) AS03-adjuvanted prepandemic candidate influenza vaccines in children aged 3 to 9 years: a phase ii, randomized, open, controlled study.
    Díez-Domingo J; Garcés-Sanchez M; Baldó JM; Planelles MV; Ubeda I; JuBert A; Marés J; Moris P; Garcia-Corbeira P; Dramé M; Gillard P
    Pediatr Infect Dis J; 2010 Jun; 29(6):e35-46. PubMed ID: 20375709
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and efficacy of vaccination against influenza in patients with rheumatoid arthritis.
    Elkayam O
    Clin Dev Immunol; 2006; 13(2-4):349-51. PubMed ID: 17162376
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.
    Englund JA; Walter EB; Gbadebo A; Monto AS; Zhu Y; Neuzil KM
    Pediatrics; 2006 Sep; 118(3):e579-85. PubMed ID: 16950949
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Virosomal influenza vaccine: a safe and effective influenza vaccine with high efficacy in elderly and subjects with low pre-vaccination antibody titers.
    de Bruijn IA; Nauta J; Gerez L; Palache AM
    Virus Res; 2004 Jul; 103(1-2):139-45. PubMed ID: 15163502
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improving influenza vaccines.
    Sambhara S; Rappuoli R
    Expert Rev Vaccines; 2012 Aug; 11(8):871-2. PubMed ID: 23002964
    [No Abstract]   [Full Text] [Related]  

  • 32. Safety and immunogenicity of adjuvanted inactivated split-virion and whole-virion influenza A (H5N1) vaccines in children: a phase I-II randomized trial.
    Wu J; Liu SZ; Dong SS; Dong XP; Zhang WL; Lu M; Li CG; Zhou JC; Fang HH; Liu Y; Liu LY; Qiu YZ; Gao Q; Zhang XM; Chen JT; Zhong X; Yin WD; Feng ZJ
    Vaccine; 2010 Aug; 28(38):6221-7. PubMed ID: 20638454
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunogenicity and safety of intradermal influenza immunization at a reduced dose in healthy children.
    Chiu SS; Peiris JS; Chan KH; Wong WH; Lau YL
    Pediatrics; 2007 Jun; 119(6):1076-82. PubMed ID: 17545373
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized clinical trial assessing immunogenicity and safety of a double dose of virosomal-adjuvanted influenza vaccine administered to unprimed children aged 6-35 months.
    Esposito S; Marchisio P; Ansaldi F; Bianchini S; Pacei M; Baggi E; Trabattoni D; Icardi G; Principi N
    Vaccine; 2010 Aug; 28(38):6137-44. PubMed ID: 20670909
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of live attenuated influenza vaccine in children against influenza B viruses by lineage and antigenic similarity.
    Belshe RB; Coelingh K; Ambrose CS; Woo JC; Wu X
    Vaccine; 2010 Feb; 28(9):2149-56. PubMed ID: 20003926
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current evidence on intradermal influenza vaccines administered by Soluvia™ licensed micro injection system.
    Icardi G; Orsi A; Ceravolo A; Ansaldi F
    Hum Vaccin Immunother; 2012 Jan; 8(1):67-75. PubMed ID: 22293531
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial.
    Keitel W; Groth N; Lattanzi M; Praus M; Hilbert AK; Borkowski A; Tsai TF
    Vaccine; 2010 Jan; 28(3):840-8. PubMed ID: 19835829
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunogenicity and safety of a monovalent vaccine for the 2009 pandemic influenza virus A (H1N1) in children and adolescents.
    Lu CY; Shao PL; Chang LY; Huang YC; Chiu CH; Hsieh YC; Lin TY; Huang LM
    Vaccine; 2010 Aug; 28(36):5864-70. PubMed ID: 20600484
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations.
    Atmar RL; Keitel WA; Patel SM; Katz JM; She D; El Sahly H; Pompey J; Cate TR; Couch RB
    Clin Infect Dis; 2006 Nov; 43(9):1135-42. PubMed ID: 17029131
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune response to influenza vaccination in children and adults with asthma: effect of corticosteroid therapy.
    Hanania NA; Sockrider M; Castro M; Holbrook JT; Tonascia J; Wise R; Atmar RL;
    J Allergy Clin Immunol; 2004 Apr; 113(4):717-24. PubMed ID: 15100679
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.